Biomarker testing plays a critical role in tailored treatment by identifying specific genes, proteins, and other molecules that can provide information about the cancer and its potential response to treatment. Common biomarkers include PD-L1, which can indicate whether immunotherapy is a viable option, and EGFR, which can be targeted by specific drugs in non-small cell lung cancer. Comprehensive biomarker testing allows for more accurate and effective treatment planning.
